RU2017143776A - Пролекарства альвоцидиба, имеющие повышенную биодоступность - Google Patents
Пролекарства альвоцидиба, имеющие повышенную биодоступность Download PDFInfo
- Publication number
- RU2017143776A RU2017143776A RU2017143776A RU2017143776A RU2017143776A RU 2017143776 A RU2017143776 A RU 2017143776A RU 2017143776 A RU2017143776 A RU 2017143776A RU 2017143776 A RU2017143776 A RU 2017143776A RU 2017143776 A RU2017143776 A RU 2017143776A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- following structure
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (41)
1. Соединение, имеющее следующую структуру (I):
(I)
или его стереоизомер, таутомер или фармацевтически приемлемая соль, где:
один из R1, R2 или R3 является -P(=O)(OH)2, и два другие из R1, R2 и R3 каждый является H.
2. Соединение по п. 1, имеющее следующую структуру (I′):
(I′)
3. Соединение по п. 1, имеющее следующую структуру (IA):
(IA)
4. Соединение по п. 3, имеющее следующую структуру (IA′):
(IA′)
5. Соединение по п. 1, имеющее следующую структуру (IB):
(IB)
6. Соединение по п. 5, имеющее следующую структуру (IB′):
(IB′)
7. Соединение по п. 1, имеющее следующую структуру (IC):
(IC)
8. Соединение по п. 7, имеющее следующую структуру (IC′):
(IC′)
9. Фармацевтически приемлемая соль соединения по любому из пп. 1-8.
10. Фармацевтически приемлемая соль по п. 9, где фармацевтически приемлемой солью является основно-аддитивная соль.
11. Фармацевтически приемлемая соль по п. 10, где фармацевтически приемлемой солью является соль натрия.
12. Фармацевтически приемлемая соль по п. 9, где фармацевтически приемлемой солью является кислотно-аддитивная соль.
13. Фармацевтически приемлемая соль по п. 12, где фармацевтически приемлемой солью является гидрохлорид.
14. Фармацевтическая композиция, содержащая фармацевтически приемлемый носитель или наполнитель и соединение по любому из пп. 1-13.
15. Фармацевтическая композиция по п. 14, где фармацевтическая композиция составлена для перорального введения.
16. Способ лечения заболевания, связанного со сверхэкспрессией циклинзависимой киназы (ЦЗК) у млекопитающих, нуждающихся в таковом, где способ включает введение терапевтически эффективного количества соединения по любому из пп. 1-13 или композиции по любому из пп. 14 или 15 млекопитающему.
17. Способ по п. 16, где заболеванием является рак.
18. Способ по п. 17, где раком является гемобластоз.
19. Способ по п. 18, где гемобластоз выбирают острого миелогенного лейкоза (ОМЛ), множественной миеломы, фолликулярной лимфомы, острого лимфобластного лейкоза (ОЛЛ), хронического лимфоцитарного лейкоза (ХЛЛ) и неходжкинской лимфомы.
20. Способ по п. 19, где гемолбластозом является острый миелогенный лейкоз (ОМЛ).
21. Способ по п. 19, где гемобластозом является хронический лимфоцитарный лейкоз (ХЛЛ).
22. Способ по п. 18, где гемобластозом является миелодиспластический синдром (МДС).
23. Способ по любому из пп. 16-22, где способ включает пероральное введение соединения по любому из пп. 1-13 или композиции по любому из пп. 14 или 15 млекопитающему.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562163188P | 2015-05-18 | 2015-05-18 | |
US62/163,188 | 2015-05-18 | ||
PCT/US2016/033099 WO2016187316A1 (en) | 2015-05-18 | 2016-05-18 | Alvocidib prodrugs having increased bioavailability |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017143776A true RU2017143776A (ru) | 2019-06-18 |
RU2017143776A3 RU2017143776A3 (ru) | 2019-11-08 |
RU2752729C2 RU2752729C2 (ru) | 2021-07-30 |
Family
ID=56087537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017143776A RU2752729C2 (ru) | 2015-05-18 | 2016-05-18 | Пролекарства альвоцидиба, имеющие повышенную биодоступность |
Country Status (20)
Country | Link |
---|---|
US (5) | US9758539B2 (ru) |
EP (3) | EP3527574B1 (ru) |
JP (4) | JP6510075B2 (ru) |
KR (1) | KR102608921B1 (ru) |
CN (2) | CN107849073B (ru) |
AU (2) | AU2016264212B2 (ru) |
BR (1) | BR112017024933A8 (ru) |
CA (1) | CA2985804A1 (ru) |
CY (1) | CY1121851T1 (ru) |
DK (2) | DK3298021T3 (ru) |
ES (2) | ES2739749T3 (ru) |
HK (1) | HK1251941B (ru) |
HU (1) | HUE045585T2 (ru) |
IL (1) | IL255465B (ru) |
MX (1) | MX2017014645A (ru) |
PL (1) | PL3298021T3 (ru) |
PT (1) | PT3298021T (ru) |
RU (1) | RU2752729C2 (ru) |
TR (1) | TR201911032T4 (ru) |
WO (1) | WO2016187316A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10202356B2 (en) | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
AU2015372441A1 (en) | 2014-12-23 | 2017-08-10 | Automed Pty Ltd | Delivery apparatus, system and associated methods |
MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
KR102608921B1 (ko) * | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
WO2019200243A1 (en) * | 2018-04-13 | 2019-10-17 | Tolero Pharmaceuticals, Inc. | Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer |
WO2019246421A1 (en) * | 2018-06-21 | 2019-12-26 | Tolero Pharmaceuticals, Inc. | Deuterated alvocidib and alvocidib prodrugs |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
MX2021005075A (es) * | 2018-12-07 | 2021-07-15 | Sumitomo Pharma Oncology Inc | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. |
BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
WO2020191326A1 (en) * | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
AU2020245437A1 (en) | 2019-03-22 | 2021-09-30 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
US20220305037A1 (en) | 2019-07-08 | 2022-09-29 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of Cancer |
JP2023504515A (ja) | 2019-12-05 | 2023-02-03 | スミトモ ファーマ オンコロジー, インコーポレイテッド | 骨髄異形成症候群の処置のための併用療法 |
US11957542B2 (en) * | 2020-04-30 | 2024-04-16 | Automed Patent Holdco, Llc | Sensing complete injection for animal injection device |
WO2023027032A1 (ja) | 2021-08-23 | 2023-03-02 | 住友ファーマ株式会社 | 自己分解型cdk9阻害剤プロドラッグ及びそれを内封するリポソーム |
Family Cites Families (191)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2338043A1 (fr) | 1976-01-13 | 1977-08-12 | Delmar Chem | Derives de 4-arylpiperidine et procedes de production |
US4132710A (en) | 1976-12-20 | 1979-01-02 | Ayerst, Mckenna And Harrison, Ltd. | [2]Benzopyrano[3,4-c]pyridines and process therefor |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IN164232B (ru) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JP2691986B2 (ja) | 1987-08-28 | 1997-12-17 | チッソ株式会社 | ピリジン骨格を有する光学活性化合物の製造法 |
DE3743824C2 (de) | 1987-12-23 | 1997-03-06 | Hoechst Ag | Verfahren zur enzymatischen Racematspaltung von racemischen Alkoholen mit/in Vinylestern durch Umesterung |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3836676A1 (de) | 1988-10-28 | 1990-05-03 | Hoechst Ag | Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel |
US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JPH0641075A (ja) | 1990-09-01 | 1994-02-15 | Kazuo Achinami | 新規な1,4−ジヒドロピリジン化合物及びその製造方法 |
EP0507278A3 (en) | 1991-04-02 | 1993-12-15 | Hoechst Ag | Immobilised biocatalyser, its preparation and use for ester synthesis in a column reactor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
GB9422836D0 (en) | 1994-11-11 | 1995-01-04 | Wainscoat James | Monitoring malignant disease |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
EP0845043B1 (en) | 1995-07-28 | 2007-06-27 | Marie Curie Cancer Care | Transport proteins and their uses |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
EP0888458A4 (en) | 1996-02-20 | 2004-05-06 | Sloan Kettering Institutefor C | COMBINATION OF PROTEIN KINASE C INHIBITORS AND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
US6087366A (en) | 1996-03-07 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
CA2277100C (en) | 1997-01-06 | 2005-11-22 | Pfizer Inc. | Cyclic sulfone derivatives |
TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
GB9704444D0 (en) | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
CA2289102A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
ATE263147T1 (de) | 1997-08-08 | 2004-04-15 | Pfizer Prod Inc | Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren |
ATE368665T1 (de) | 1997-08-22 | 2007-08-15 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
WO1999014321A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
AU9402898A (en) | 1997-09-26 | 1999-04-23 | Washington University | Cell death agonists |
CN1280580A (zh) | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
DE19802449A1 (de) | 1998-01-23 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin |
US6437136B2 (en) | 1998-01-23 | 2002-08-20 | Aventis Pharma Deutschland Gmbh | Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
DE19809649A1 (de) | 1998-03-06 | 1999-09-09 | Hoechst Marion Roussel De Gmbh | Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester |
JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
HUP0103617A2 (hu) | 1998-05-29 | 2002-02-28 | Sugen, Inc. | Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása |
UA60365C2 (ru) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего |
FR2780056B1 (fr) | 1998-06-18 | 2000-08-04 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre |
WO2000006134A2 (en) | 1998-07-30 | 2000-02-10 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
US6268499B1 (en) | 1998-08-10 | 2001-07-31 | Hoffman-La Roche Inc. | Process and intermediates for preparation of substituted piperidine-epoxides |
DE19981729D2 (de) | 1998-08-29 | 2001-08-09 | Ghyczy Miklos | Pharmazeutisches und/oder diätetisches Produkt |
DK1004578T3 (da) | 1998-11-05 | 2004-06-28 | Pfizer Prod Inc | 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
WO2000059526A1 (en) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
US6511993B1 (en) | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
AU6906100A (en) | 1999-08-16 | 2001-03-13 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
US6821990B2 (en) | 2000-01-18 | 2004-11-23 | Aventis Pharma Deutschland Gmbh | Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one |
US6576647B2 (en) | 2000-01-18 | 2003-06-10 | Aventis Pharmaceuticals Inc. | Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one |
CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
CA2430376A1 (en) | 2000-12-08 | 2002-06-13 | David J. Carini | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
EP1427407A4 (en) | 2001-03-23 | 2005-05-11 | Luitpold Pharm Inc | CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS |
ATE556706T1 (de) | 2001-03-23 | 2012-05-15 | Luitpold Pharm Inc | Fettalkohol-arzneimittel-konjugate |
KR20030026069A (ko) | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
WO2003027237A2 (en) | 2001-09-24 | 2003-04-03 | Blood Center Research Foundation | Method of modulating or examining ku70 levels in cells |
WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
WO2003057158A2 (en) | 2001-12-31 | 2003-07-17 | Dana-Farber Cancer Institute, Inc. | Method of treating apoptosis and compositions thereof |
DE60325184D1 (de) | 2002-03-01 | 2009-01-22 | Immunomedics Inc | Rs7 antikörper |
US20040106647A1 (en) | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
EP1590363A4 (en) | 2002-09-09 | 2006-11-02 | Dana Farber Cancer Inst Inc | BH3-PEPTIDES AND METHOD FOR THEIR USE |
WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
EP1620109A2 (en) * | 2003-04-25 | 2006-02-01 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
GB0315259D0 (en) | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
JP5105874B2 (ja) * | 2003-07-18 | 2012-12-26 | アムジエン・インコーポレーテツド | 肝細胞増殖因子に対する特異的結合因子 |
CN1302004C (zh) | 2003-08-22 | 2007-02-28 | 浙江海正药业股份有限公司 | 一种阿糖胞苷的制备方法 |
PT1680443E (pt) | 2003-11-05 | 2013-12-11 | Harvard College | Péptidos alfa-helicoidais estabilizados e suas utilizações |
AU2005286833B2 (en) * | 2004-09-21 | 2012-02-16 | Nanoshift, Llc | Sulfonyl hydrazines as hypoxia-selective antineoplastic agents |
WO2006069186A2 (en) | 2004-12-22 | 2006-06-29 | The Ohio State Research Foundation | Small molecule bcl-xl/bcl-2 binding inhibitors |
WO2006101846A1 (en) | 2005-03-16 | 2006-09-28 | Aventis Pharmaceuticals Inc. | Dosing regimen of flavopiridol for treating cancer in particular cll |
WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
BRPI0616731A2 (pt) * | 2005-09-09 | 2016-08-23 | Analytecon Sa | derivados de isoquinolina como inibidores do igf-1r |
EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
WO2007129062A1 (en) | 2006-05-08 | 2007-11-15 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
WO2008021484A2 (en) | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
BRPI0807897A2 (pt) | 2007-03-01 | 2014-06-17 | Supergen Inc | Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase. |
GB0706633D0 (en) | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
RU2438664C2 (ru) | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
ATE538652T1 (de) | 2007-05-15 | 2012-01-15 | Piramal Life Sciences Ltd | Synergistische pharmazeutische kombination für die behandlung von krebs |
US20090030005A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
JP5783721B2 (ja) | 2007-09-26 | 2015-09-24 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Bcl−2ファミリーポリペプチドを調節する方法及び組成物 |
CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
WO2009100335A1 (en) * | 2008-02-08 | 2009-08-13 | Wyeth | Phosphate derivatives of substituted benzoxazoles |
EP2304047A4 (en) | 2008-05-07 | 2012-12-26 | Eutropics Pharmaceuticals Inc | ANTIBODIES TAKEN UPON HETERODIMES OF THE BCL-2 FAMILY AND THEIR USES |
EP2307002B1 (en) | 2008-06-09 | 2013-01-02 | Cyclacel Limited | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
US20100061982A1 (en) * | 2008-09-10 | 2010-03-11 | Wyeth | 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
JP2012517241A (ja) | 2009-02-11 | 2012-08-02 | アボット・ラボラトリーズ | Bcl−2ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物 |
EP3243527B1 (en) | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
WO2011088137A2 (en) | 2010-01-12 | 2011-07-21 | H. Lee Moffitt Cancer Center & Research Institute | Bad pathway gene signature |
US8372819B2 (en) | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
WO2011143660A2 (en) | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
US9051305B2 (en) | 2011-03-08 | 2015-06-09 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
MX344580B (es) | 2011-06-14 | 2016-12-20 | Novartis Ag | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. |
EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
US9012215B2 (en) | 2011-09-22 | 2015-04-21 | The Johns Hopkins University | Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research |
US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
WO2013082660A1 (en) | 2011-12-09 | 2013-06-13 | Alfred Health | Prediction method |
WO2013138702A2 (en) | 2012-03-15 | 2013-09-19 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
CA2868081C (en) | 2012-03-20 | 2021-01-05 | Loren D. Walensky | Inhibition of mcl-1 and/or bfl-1/a1 |
EP2847592A4 (en) | 2012-05-10 | 2016-05-04 | Eutropics Pharmaceuticals Inc | SURROGATE FUNCTIONAL DIAGNOSTIC TEST FOR CANCER |
WO2013182519A1 (en) | 2012-06-04 | 2013-12-12 | Universitaet Basel | Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer |
WO2013188355A1 (en) | 2012-06-12 | 2013-12-19 | Merck Sharp & Dohme Corp. | Cdk inhibitor for treating refractory chronic lymphocytic leukemia |
US20150150869A1 (en) | 2012-06-20 | 2015-06-04 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
US10393733B2 (en) | 2012-09-19 | 2019-08-27 | Dana-Farber Cancer Institute, Inc. | Dynamic BH3 profiling |
US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
EP2912178B1 (en) | 2012-10-25 | 2020-06-17 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
WO2015010094A1 (en) | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
JP6663852B2 (ja) | 2013-09-19 | 2020-03-13 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Bh3プロファイリングの方法 |
CA2920192A1 (en) | 2013-09-27 | 2015-04-02 | Immunomedics, Inc. | Anti-trop-2 antibody-drug conjugates and uses thereof |
JP6538044B2 (ja) | 2013-10-30 | 2019-07-03 | ユートロピクス ファーマシューティカルズ, インコーポレイテッド | 化学療法感受性および化学毒性を判定する方法 |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
WO2015130585A1 (en) | 2014-02-28 | 2015-09-03 | Merck Sharp & Dohme Corp. | Method for treating cancer |
WO2015161247A1 (en) | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
DK3194443T3 (da) | 2014-09-17 | 2021-09-27 | Novartis Ag | Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi |
CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
RU2737508C2 (ru) | 2014-11-07 | 2020-12-01 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Способы воздействия на транскрипционный контроль в суперэнхансерных областях |
CA2974240A1 (en) | 2015-01-12 | 2016-07-21 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
EP3270945A4 (en) | 2015-03-18 | 2018-09-05 | Massachusetts Institute of Technology | Selective mcl-1 binding peptides |
US20180100859A1 (en) | 2015-03-24 | 2018-04-12 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
WO2016161248A1 (en) | 2015-04-02 | 2016-10-06 | Tolero Pharmaceuticals, Inc. | Targeting pim kinases in combination with btk inhibition |
MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
JP6802185B2 (ja) | 2015-04-27 | 2020-12-16 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術 |
KR102608921B1 (ko) * | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
US20190077840A1 (en) | 2015-10-30 | 2019-03-14 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
CN105919955A (zh) | 2016-06-13 | 2016-09-07 | 佛山市腾瑞医药科技有限公司 | 一种鲁索利替尼制剂及其应用 |
US11279694B2 (en) * | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
US10132797B2 (en) | 2016-12-19 | 2018-11-20 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
MX2021006544A (es) * | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
-
2016
- 2016-05-18 KR KR1020177036133A patent/KR102608921B1/ko active IP Right Grant
- 2016-05-18 EP EP19167051.2A patent/EP3527574B1/en active Active
- 2016-05-18 WO PCT/US2016/033099 patent/WO2016187316A1/en active Application Filing
- 2016-05-18 EP EP22166479.0A patent/EP4086264B1/en active Active
- 2016-05-18 CA CA2985804A patent/CA2985804A1/en active Pending
- 2016-05-18 ES ES16725997T patent/ES2739749T3/es active Active
- 2016-05-18 AU AU2016264212A patent/AU2016264212B2/en active Active
- 2016-05-18 DK DK16725997.7T patent/DK3298021T3/da active
- 2016-05-18 MX MX2017014645A patent/MX2017014645A/es unknown
- 2016-05-18 US US15/158,206 patent/US9758539B2/en active Active
- 2016-05-18 HU HUE16725997A patent/HUE045585T2/hu unknown
- 2016-05-18 CN CN201680028628.XA patent/CN107849073B/zh active Active
- 2016-05-18 PT PT16725997T patent/PT3298021T/pt unknown
- 2016-05-18 JP JP2017559812A patent/JP6510075B2/ja active Active
- 2016-05-18 DK DK19167051.2T patent/DK3527574T3/da active
- 2016-05-18 PL PL16725997T patent/PL3298021T3/pl unknown
- 2016-05-18 CN CN202010157126.5A patent/CN111349118B/zh active Active
- 2016-05-18 ES ES19167051T patent/ES2921350T3/es active Active
- 2016-05-18 TR TR2019/11032T patent/TR201911032T4/tr unknown
- 2016-05-18 RU RU2017143776A patent/RU2752729C2/ru active
- 2016-05-18 EP EP16725997.7A patent/EP3298021B1/en active Active
- 2016-05-18 BR BR112017024933A patent/BR112017024933A8/pt active Search and Examination
-
2017
- 2017-08-09 US US15/673,213 patent/US10259835B2/en active Active
- 2017-11-06 IL IL255465A patent/IL255465B/en unknown
-
2018
- 2018-08-17 JP JP2018153504A patent/JP6695940B2/ja active Active
- 2018-09-03 HK HK18111270.8A patent/HK1251941B/zh unknown
-
2019
- 2019-02-19 US US16/279,958 patent/US10562925B2/en active Active
- 2019-07-26 CY CY20191100801T patent/CY1121851T1/el unknown
- 2019-12-26 US US16/727,693 patent/US20200131210A1/en not_active Abandoned
-
2020
- 2020-04-22 JP JP2020075973A patent/JP6883688B2/ja active Active
-
2021
- 2021-01-20 AU AU2021200343A patent/AU2021200343A1/en not_active Abandoned
- 2021-05-07 US US17/314,896 patent/US20210261585A1/en active Pending
- 2021-05-10 JP JP2021079708A patent/JP7133680B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
JP2018517686A5 (ru) | ||
JP2018522038A5 (ru) | ||
JP2014510729A5 (ru) | ||
RU2018106886A (ru) | Комбинированные терапии для лечения рака | |
RU2018137687A (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
RU2020114660A (ru) | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 | |
JP2016515561A5 (ru) | ||
JP2018525441A5 (ru) | ||
JP2016501221A5 (ru) | ||
JP2017533222A5 (ru) | ||
JP2014511892A5 (ru) | ||
RU2015125307A (ru) | Комбинированная терапия | |
JP2014511891A5 (ru) | ||
RU2018107668A (ru) | Пиразолпиримидиновое производное и его применение | |
JP2015505816A5 (ru) | ||
JP2009536620A5 (ru) | ||
JP2014505735A5 (ru) | ||
JP2018524347A5 (ru) | ||
RU2015143843A (ru) | Ингибиторы гистондеацетилазы | |
RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
JP2016501838A5 (ru) | ||
RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
HRP20120918T1 (hr) | Aminopirazolski spoj | |
RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HZ9A | Changing address for correspondence with an applicant |